References

Nucleos(t)ide analogues and Hepatitis B virus-related hepatocellular carcinoma: a literature review

10.1177/2040206620921331 · 2020 · External reference

Tremelimumab plus Durvalumab in unresectable hepatocellular carcinoma

10.1056/evidoa2100070 · 2022 · External reference

The role of cccDNA in HBV maintenance

10.3390/v9060156 · 2017 · External reference

Correction: amin et al. Hepatocellular Carcinoma: a comprehensive review

10.3390/diseases13070207 · 2025 · External reference

Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapy

10.1007/s00262-022-03254-w · 2023 · External reference

Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma

10.1038/nrc3449 · 2013 · External reference

The immune tolerant phase of chronic HBV infection: new perspectives on an old concept

10.1038/cmi.2014.79 · 2015 · External reference

Hepatitis C Guidance 2023 update: AASLD-IDSA recommendations for testing, managing, and treating Hepatitis C Virus infection

10.1093/cid/ciad319 · 2023 · External reference

Understanding the tumor immune microenvironment (TIME) for effective therapy

10.1038/s41591-018-0014-x · 2018 · External reference

Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues

10.1053/j.gastro.2012.07.014 · 2012 · External reference

Unresolved reference

2024 · External reference

Recurrence risk factors for chronic hepatitis B virus-infected patients who achieve functional cure with pegylated interferon-alpha-2b-based therapy: a multicenter pilot study

10.1186/s12985-025-02761-3 · 2025 · External reference

Predictors of durable Hepatitis B surface antigen loss after pegylated interferon-based therapy in patients with Hepatitis B e antigen-negative chronic Hepatitis B: a multicenter real-world study

10.1093/infdis/jiaf198 · 2025 · External reference

A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma

10.1097/01.sla.0000201480.65519.b8 · 2006 · External reference

The effect of antiviral therapy on patients with hepatitis B virus-related hepatocellular carcinoma after curative resection: a systematic review and meta-analysis

10.2147/ott.s150281 · 2017 · External reference

Tumor-associated macrophages in liver cancer: from mechanisms to therapy

10.1002/cac2.12345 · 2022 · External reference

Immunotherapy for hepatocellular carcinoma

2024 · External reference

Impact of antiviral therapy on post-hepatectomy outcome for hepatitis B-related hepatocellular carcinoma

10.3748/wjg.v20.i20.6006 · 2014 · External reference

Multiplex genome engineering using CRISPR/Cas systems

10.1126/science.1231143 · 2013 · External reference

Guidance for design and endpoints of clinical trials in chronic hepatitis B - report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference(double dagger)

10.1016/j.jhep.2019.11.003 · 2020 · External reference

Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor

10.1038/nature17170 · 2016 · External reference

Hepatitis B virus reactivation in cancer patients receiving chemotherapy-A systematic review and meta-analysis

10.1053/j.seminoncol.2024.08.001 · 2024 · External reference

Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis

10.1007/s00432-022-04133-8 · 2023 · External reference

Hepatocellular carcinoma in the setting of chronic Hepatitis B virus infection: tumor recurrence and survival rates after liver transplantation

10.1016/j.transproceed.2015.02.021 · 2015 · External reference

Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team

10.1016/j.jhep.2013.08.011 · 2014 · External reference

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

10.1016/s0140-6736(17)31046-2 · 2017 · External reference

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

10.1053/j.gastro.2007.04.061 · 2007 · External reference

Navigating the latest Hepatitis B virus reactivation guidelines

10.3390/diseases13110355 · 2025 · External reference

EASL Clinical Practice Guidelines on the management of hepatitis B virus infection

10.1016/j.jhep.2025.03.018 · 2025 · External reference

Targeting host innate and adaptive immunity to achieve the functional cure of chronic Hepatitis B

10.3390/vaccines8020216 · 2020 · External reference

Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma

10.1056/nejmoa1915745 · 2020 · External reference

Interactions between tumor microenvironment and resistance to transarterial and systemic treatments for HCC

2025 · External reference

Hepatic fibrosis – overview

10.1016/j.tox.2008.06.013 · 2008 · External reference

Role of hepatitis B surface antibody in seroreversion of hepatitis B surface antigen in patients achieving hepatitis B surface antigen loss with pegylated interferon-based therapy

10.1111/jvh.13734 · 2022 · External reference

Comprehensive analysis of the immunosuppressive function of regulatory T cells in Human hepatocellular carcinoma tissues

10.1177/10732748241251580 · 2024 · External reference

Hepatitis B e antigen and the risk of hepatocellular carcinoma

10.1056/nejm200211213472119 · 2002 · External reference

Antiviral resistance and hepatitis B therapy

10.1002/hep.22900 · 2009 · External reference

Serum HBV pgRNA as a clinical marker for cccDNA activity

10.1016/j.jhep.2016.09.028 · 2017 · External reference

Immune function of plasmacytoid dendritic cells, natural killer cells, and their crosstalk in HBV infection

10.1002/rmv.2007 · 2018 · External reference

Feasibility of combining adjuvant transarterial chemoembolization with nucleos(t)ide analog therapy for patients with HBV-associated hepatocellular carcinoma after hepatectomy

10.3892/mco.2016.871 · 2016 · External reference

Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update

10.1200/jco.23.02745 · 2024 · External reference

The current status and future of targeted-immune combination for hepatocellular carcinoma

10.3389/fimmu.2024.1418965 · 2024 · External reference

The dual role of regulatory T cells in hepatitis B virus infection and related hepatocellular carcinoma

10.1111/imm.13738 · 2024 · External reference

Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor

10.1002/hep.23054 · 2009 · External reference

Reactivation of hepatitis B

10.1002/hep.22945 · 2009 · External reference

Inhibitory PD-1 axis maintains high-avidity stem-like CD8(+) T cells

10.1038/s41586-025-09440-x · 2026 · External reference

Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection

10.1002/hep.26180 · 2013 · External reference

Phase 3 results of Bepirovirsen treatment for chronic Hepatitis B Virus infection

10.1056/nejmoa2515131 · 2026 · External reference

Global burden of hepatitis B virus: current status, missed opportunities and a call for action

10.1038/s41575-023-00760-9 · 2023 · External reference

Inhibition of viral replication reduces transcriptionally active distinct Hepatitis B virus integrations with implications on host gene dysregulation

10.1053/j.gastro.2021.12.286 · 2022 · External reference

Antiviral treatments eliminate the adverse impacts of high baseline HBV loads on the survival of HBV-related HCC patients

10.2147/jhc.s363123 · 2022 · External reference

Antiviral therapy reduces hepatocellular carcinoma recurrence in patients with low HBV-DNA levels: a randomized controlled trial

10.1097/sla.0000000000002727 · 2018 · External reference

Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update

10.1200/jco.20.01757 · 2020 · External reference

Hepatitis B virus screening for patients with cancer before therapy: american Society of Clinical Oncology provisional Clinical opinion update

10.1200/jco.2015.61.3745 · 2015 · External reference

Reactivation of Hepatitis B virus among patients with cancer receiving immunotherapy

10.36401/jipo-20-19 · 2021 · External reference

Evaluation of hepatitis B virus reactivation prevention measures in immunosuppressed patients: current status and effectiveness

10.21037/tgh-24-103 · 2025 · External reference

Predictors of HBsAg seroclearance in patients with chronic HBV infection treated with pegylated interferon-alpha: a systematic review and meta-analysis

10.1007/s12072-024-10648-8 · 2024 · External reference

A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity

10.1126/science.1225829 · 2012 · External reference

Targeting cancer associated fibroblasts in liver fibrosis and liver cancer using nanocarriers

10.3390/cells9092027 · 2020 · External reference

CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame

2015 · External reference

Development of an in vivo delivery system for CRISPR/Cas9-mediated targeting of hepatitis B virus cccDNA

10.1016/j.virusres.2020.198191 · 2020 · External reference

Nucleos(t)ide analogues to treat hepatitis B virus-related hepatocellular carcinoma after radical resection

10.4254/wjh.v6.i9.652 · 2014 · External reference

Hepatocellular carcinoma - origins and outcomes

10.1056/nejmcibr2106594 · 2021 · External reference

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial

10.1016/s1470-2045(22)00326-6 · 2022 · External reference

Major pathways involved in macrophage polarization in cancer

10.3389/fimmu.2022.1026954 · 2022 · External reference

Management of hepatocellular carcinoma in 2024: the multidisciplinary paradigm in an evolving treatment landscape

10.3390/cancers16030666 · 2024 · External reference

MVA-HBVac-A novel vaccine vector that allows pan-genotypic targeting of hepatitis B virus by therapeutic vaccination

10.1016/j.omtn.2025.102641 · 2025 · External reference

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

10.1016/s0140-6736(18)30207-1 · 2018 · External reference

Advances in discovery of novel investigational agents for functional cure of chronic hepatitis B: a comprehensive review of phases II and III therapeutic agents

10.4254/wjh.v16.i3.331 · 2024 · External reference

Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

10.1016/j.jhep.2024.07.017 · 2025 · External reference

APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy

10.1007/s12072-021-10239-x · 2021 · External reference

Mechanisms of HBV-induced hepatocellular carcinoma

10.1016/j.jhep.2016.02.021 · 2016 · External reference

Removal of integrated Hepatitis B virus DNA using CRISPR-Cas9

10.3389/fcimb.2017.00091 · 2017 · External reference

Spatial proteomics of immune microenvironment in nonalcoholic steatohepatitis-associated hepatocellular carcinoma

10.1097/hep.0000000000000591 · 2024 · External reference

The important role of myeloid-derived suppressor cells: from hepatitis to liver cancer

10.1016/j.bbcan.2025.189329 · 2025 · External reference

Early and late recurrence after hepatectomy in patients with low-level HBV-DNA hepatocellular carcinoma under antiviral therapy

10.1186/s13027-022-00468-6 · 2022 · External reference

Impact of preoperative antiviral therapy on the prognosis of hepatitis B virus-related hepatocellular carcinoma

10.1186/s12885-024-12031-0 · 2024 · External reference

HBV reactivation and prognosis after systemic therapy in HCC with undetectable HBV DNA: a multicenter retrospective study

2025 · External reference

Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma

10.1136/gutjnl-2018-316510 · 2019 · External reference

The scientific basis of combination therapy for chronic hepatitis B functional cure

10.1038/s41575-022-00724-5 · 2023 · External reference

Tenofovir versus entecavir on the prognosis of hepatitis B-related hepatocellular carcinoma after surgical resection: a randomised controlled trial

10.1097/js9.0000000000000554 · 2023 · External reference

Benefits of entecavir therapy in HBV-related hepatocellular carcinoma patients with compensated cirrhosis after hepatectomy: a ten-year retrospective cohort study

10.1016/j.ejso.2025.109621 · 2025 · External reference

HBV reactivation and its management in HBV-related HCC patients undergoing HAIC-TKI-ICI therapy: a multicenter study

10.1016/j.isci.2025.112689 · 2025 · External reference

Clinical benefit of antiviral agents for hepatocellular carcinoma patients with low preoperative HBV-DNA loads undergoing curative resection: a meta-analysis

2021 · External reference

The emerging challenge of non-cirrhotic MASLD-related hepatocellular carcinoma: etiology, immunopathology, and precision oncology

10.1159/000550163 · 2025 · External reference

Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival

10.1053/jhep.2003.50047 · 2003 · External reference

Hepatocellular carcinoma

10.1038/s41572-020-00240-3 · 2021 · External reference

Molecular pathogenesis and systemic therapies for hepatocellular carcinoma

10.1038/s43018-022-00357-2 · 2022 · External reference

Sorafenib in advanced hepatocellular carcinoma

10.1056/nejmoa0708857 · 2008 · External reference

Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions

10.1053/j.gastro.2017.02.009 · 2017 · External reference

TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma

10.1186/s12885-023-10694-9 · 2023 · External reference

Novel drug development in chronic Hepatitis B infection: capsid assembly modulators and nucleic acid polymers

10.1016/j.cld.2023.05.004 · 2023 · External reference

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

10.1016/s0140-6736(12)61425-1 · 2013 · External reference

Epidemiology of hepatocellular carcinoma

10.1002/hep.31288 · 2021 · External reference

Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability

10.1016/j.cld.2015.01.001 · 2015 · External reference

Risk factors for recurrence in patients with hepatocellular carcinoma after curative resection or ablation

10.2147/jhc.s552316 · 2025 · External reference

Advances in the treatment of hepatocellular carcinoma: an overview of the current and evolving therapeutic landscape for clinicians

2025 · External reference

A simple scoring system to estimate perioperative mortality following liver resection for primary liver malignancy-the Hepatectomy Risk Score (HeRS)

10.21037/hbsn.2020.03.12 · 2021 · External reference

Induction of IFN-lambda3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection

10.1136/gutjnl-2016-312653 · 2018 · External reference

Immunomodulatory mechanism of acyclic nucleoside phosphates in treatment of Hepatitis B Virus infection

10.1002/hep.30956 · 2020 · External reference

Entecavir versus tenofovir for prevention of hepatitis B virus-associated hepatocellular carcinoma after curative resection: study protocol for a randomized, open-label trial

10.1186/s13063-023-07742-x · 2024 · External reference

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

10.1038/s41586-021-03362-0 · 2021 · External reference

The current landscape of immune checkpoint blockade in hepatocellular carcinoma: a review

10.1001/jamaoncol.2020.3381 · 2021 · External reference

Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study

10.1016/s2468-1253(18)30056-6 · 2018 · External reference

Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation

10.1097/00000658-200203000-00009 · 2002 · External reference

Looking toward the future: emerging therapies for hepatocellular carcinoma

2025 · External reference

Adeno-associated virus 2 CRISPR/Cas9-mediated targeting of hepatitis B virus in tree shrews

10.1016/j.virusres.2025.199550 · 2025 · External reference

American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy

10.1053/j.gastro.2014.10.039 · 2015 · External reference

Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH

10.1016/j.medcli.2020.09.022 · 2021 · External reference

BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update

10.1016/j.jhep.2021.11.018 · 2022 · External reference

Protective role of Sirtuin3 (SIRT3) in oxidative stress mediated by Hepatitis B virus X protein expression

10.1371/journal.pone.0150961 · 2016 · External reference

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study

10.1016/s1470-2045(21)00252-7 · 2021 · External reference

A global scientific strategy to cure hepatitis B

10.1016/s2468-1253(19)30119-0 · 2019 · External reference

Viral hepatitis and liver cancer

2017 · External reference

The immunology of hepatocellular carcinoma

10.1038/s41590-018-0044-z · 2018 · External reference

Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma

10.1053/j.gastro.2010.10.049 · 2011 · External reference

Risk of hepatitis B virus reactivation in cancer patients undergoing treatment with tyrosine kinase-inhibitors

10.3748/wjg.v30.i24.3052 · 2024 · External reference

Molecular biology of hepatitis B virus infection

10.1016/j.virol.2015.02.031 · 2015 · External reference

Targeting Hepatitis B virus with CRISPR/Cas9

2014 · External reference

Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy

10.1038/s41423-025-01308-4 · 2025 · External reference

Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity

10.1038/nature24302 · 2017 · External reference

Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy

10.1097/cm9.0000000000001864 · 2021 · External reference

Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives

10.1186/s13045-024-01549-2 · 2024 · External reference

Anti-HBV treatment partially restores the dysfunction of innate immune cells and unconventional T cells during chronic HBV infection

10.3389/fimmu.2025.1611976 · 2025 · External reference

AASLD Practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma

10.1097/hep.0000000000000466 · 2023 · External reference

Hepatitis B virus X and regulation of viral gene expression

10.1101/cshperspect.a021402 · 2016 · External reference

Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2021 · External reference

Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma

10.1038/ng.2295 · 2012 · External reference

Lipid nanoparticles loaded with ribonucleoprotein-oligonucleotide complexes synthesized using a microfluidic device exhibit robust genome editing and hepatitis B virus inhibition

10.1016/j.jconrel.2020.12.013 · 2021 · External reference

Single-cell RNA sequencing unveils macrophage heterogeneity and cell-cell interactions in hepatocellular carcinoma progression

10.3389/fgene.2026.1819908 · 2026 · External reference

Hepatocellular carcinoma systemic treatment update: from early to advanced stage

10.1016/j.bj.2024.100815 · 2025 · External reference

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

10.1002/hep.29800 · 2018 · External reference

Quantification of circulating HBV RNA expressed from intrahepatic cccDNA in untreated and NUC treated patients with chronic hepatitis B

10.1136/gutjnl-2023-330644 · 2024 · External reference

Trans-ancestry mutational landscape of hepatocellular carcinoma genomes

10.1038/ng.3126 · 2014 · External reference

Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads

10.1002/hep.26041 · 2013 · External reference

High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load

10.1053/j.gastro.2012.02.007 · 2012 · External reference

HBV DNA integration: molecular mechanisms and clinical implications

10.3390/v9040075 · 2017 · External reference

Hepatitis B virus DNA integration: in vitro models for investigating viral pathogenesis and persistence

10.3390/v13020180 · 2021 · External reference

Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment

10.1002/hep.29872 · 2018 · External reference

Reversion of disease manifestations after HCV eradication

10.1016/j.jhep.2016.07.039 · 2016 · External reference

The mechanism of action and therapeutic potential of tumor-associated macrophages in tumor immune evasion

2025 · External reference

The impact of proton pump inhibitors on the efficacy of immune checkpoint inhibitor combinations in patients with HBV-associated advanced hepatocellular carcinoma

10.2147/jhc.s464033 · 2024 · External reference

Effective antiviral therapy improves immunosuppressive activities in the immune microenvironment of hepatocellular carcinoma by alleviating inflammation and fibrosis

10.1002/cam4.70459 · 2024 · External reference

A phase 3, randomized trial of bulevirtide in chronic Hepatitis D

10.1056/nejmoa2213429 · 2023 · External reference

Benefits of long-term therapy with nucleos(t)ide analogues in treatment-naive patients with chronic hepatitis B

10.1080/03007995.2016.1264932 · 2017 · External reference

The CRISPR/Cas9 genome editing methodology as a weapon against human viruses

2015 · External reference

Elebsiran and PEG-IFNalpha for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial

10.1038/s41591-025-04049-z · 2026 · External reference

Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study

10.1053/j.gastro.2014.03.048 · 2014 · External reference

Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma

10.1016/j.jhep.2009.07.009 · 2009 · External reference

Hepatocellular carcinoma: advances in systemic therapies

10.12688/f1000research.145493.2 · 2024 · External reference

Efficacy of antiviral therapy with nucleotide/nucleoside analogs after curative treatment for patients with hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis

10.1016/j.clinre.2014.12.003 · 2015 · External reference

Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis

10.1186/s40249-023-01128-6 · 2023 · External reference

Comparison of clinical features and outcomes between HBV-related and non-B non-C hepatocellular carcinoma

10.1186/s13027-020-0273-2 · 2020 · External reference

Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus

10.7554/elife.00049 · 2012 · External reference

Do the therapeutic vaccines hold hope for the treatment of hepatitis B?

10.1007/s12072-025-10907-2 · 2025 · External reference

Therapeutic advances in hepatocellular carcinoma: an update from the 2024 ASCO annual meeting

10.3389/fonc.2024.1453412 · 2024 · External reference

Permanent inactivation of HBV genomes by CRISPR/Cas9-mediated non-cleavage base editing

10.1016/j.omtn.2020.03.005 · 2020 · External reference

Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival

10.1053/jhep.2001.24563 · 2001 · External reference

Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study

10.1200/jco.2012.48.5896 · 2013 · External reference

Evaluation of antiviral therapy performed after curative therapy in patients with HBV-related hepatocellular carcinoma: an updated meta-analysis

2016 · External reference

Efficacy and safety of Bepirovirsen in chronic Hepatitis B infection

10.1056/nejmoa2210027 · 2022 · External reference

VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study

10.1016/s2468-1253(24)00237-1 · 2024 · External reference

[Mechanism and clinical significance of HBV reactivation after anti-HCV therapy]

2022 · External reference

Tumor-associated macrophages in hepatocellular carcinoma: cellular plasticity and therapy resistance in crosstalk

10.1016/j.jpha.2025.101384 · 2026 · External reference

Traditional and novel virologic markers for functional cure and HBeAg loss with pegylated interferon in chronic Hepatitis B: a systematic review and meta-analysis

2026 · External reference

Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma

2016 · External reference

Targeting tumor-associated macrophages in hepatocellular carcinoma: biology, strategy, and immunotherapy

10.1038/s41420-023-01356-7 · 2023 · External reference

Single-cell landscape identifies the immunophenotypes and microenvironments of HBV-positive and HBV-negative liver cancer

10.1097/hc9.0000000000000364 · 2024 · External reference

The mechanisms and clinical significance of CD8(+) T cell exhaustion in anti-tumor immunity

2025 · External reference

Guidelines for the diagnosis and treatment of primary liver cancer (2022 Edition)

10.1159/000530495 · 2023 · External reference

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

10.1016/s1470-2045(18)30351-6 · 2018 · External reference